Related Experiment Video
Updated: Aug 2, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Hormone Receptor and HER2 Testing in Breast Cancer: Latest Questions Answered
Joanna Solarewicz1, Kimberly H Allison1
1Department of Pathology, Stanford Medicine, 300 Pasteur Drive, Stanford, CA, USA.
Abstract:
Evolving data continue to require pathologists to adjust breast cancer biomarker interpretation and reporting. ER low positive and HER2 low/ultralow are not distinct subtypes of breast cancer but have important treatment implications. ER low positive (1%-10%) cancers resemble ER-negative tumors but may still benefit from endocrine therapy. HER2 low and ultralow, as defined in DESTINY-Breast 04/06 trials, guide eligibility for trastuzumab-deruxtecan in metastatic cases. Accurate distinction between HER2 IHC 0/no staining versus 0+/some staining, is therefore, now necessary despite concerns about its reproducibility and predictive power.
More Related Videos
Related Concept Videos
Intracellular Hormone Receptors
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Signal Transduction: Overview
Typically, signal transduction involves three...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

